Pulike Biological Engineering, Inc.

SHSE:603566 Stock Report

Market Cap: CN¥4.4b

Pulike Biological Engineering Valuation

Is 603566 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603566 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603566 (CN¥13.28) is trading below our estimate of fair value (CN¥14.18)

Significantly Below Fair Value: 603566 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603566?

Key metric: As 603566 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 603566. This is calculated by dividing 603566's market cap by their current earnings.
What is 603566's PE Ratio?
PE Ratio44.7x
EarningsCN¥101.68m
Market CapCN¥4.44b

Price to Earnings Ratio vs Peers

How does 603566's PE Ratio compare to its peers?

The above table shows the PE ratio for 603566 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.3x
600351 Yabao Pharmaceutical Group
20.5xn/aCN¥4.5b
600628 Shanghai New World
99.7xn/aCN¥4.5b
002393 Tianjin Lisheng PharmaceuticalLtd
25xn/aCN¥4.5b
600479 ZhuZhou QianJin PharmaceuticalLtd
15.9xn/aCN¥4.6b
603566 Pulike Biological Engineering
44.7x33.1%CN¥4.4b

Price-To-Earnings vs Peers: 603566 is expensive based on its Price-To-Earnings Ratio (44.7x) compared to the peer average (40.3x).

Price to Earnings Ratio vs Industry

How does 603566's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
603566 44.7xIndustry Avg. 29.9xNo. of Companies30PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 603566 is expensive based on its Price-To-Earnings Ratio (44.7x) compared to the CN Pharmaceuticals industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 603566's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603566 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio44.7x
Fair PE Ratio29.3x

Price-To-Earnings vs Fair Ratio: 603566 is expensive based on its Price-To-Earnings Ratio (44.7x) compared to the estimated Fair Price-To-Earnings Ratio (29.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603566 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥13.28
CN¥16.24
+22.3%
17.3%CN¥21.00CN¥13.70n/a4
Nov ’25CN¥12.63
CN¥16.24
+28.6%
17.3%CN¥21.00CN¥13.70n/a4
Oct ’25CN¥14.12
CN¥16.24
+15.0%
17.3%CN¥21.00CN¥13.70n/a4
Sep ’25CN¥12.33
CN¥16.24
+31.7%
17.3%CN¥21.00CN¥13.70n/a4
Aug ’25CN¥12.59
CN¥17.99
+42.9%
19.9%CN¥22.00CN¥13.70n/a4
Jul ’25CN¥13.80
CN¥19.94
+44.5%
11.6%CN¥22.00CN¥16.00n/a4
Jun ’25CN¥16.95
CN¥20.24
+19.4%
9.0%CN¥22.00CN¥17.20n/a4
May ’25CN¥17.43
CN¥20.24
+16.1%
9.0%CN¥22.00CN¥17.20n/a4
Apr ’25CN¥18.21
CN¥25.07
+37.7%
22.4%CN¥30.00CN¥17.20n/a3
Mar ’25CN¥16.50
CN¥27.23
+65.1%
9.7%CN¥30.00CN¥23.70n/a3
Feb ’25CN¥15.24
CN¥28.18
+84.9%
9.9%CN¥31.00CN¥23.70n/a4
Jan ’25CN¥22.65
CN¥28.18
+24.4%
9.9%CN¥31.00CN¥23.70n/a4
Dec ’24CN¥21.13
CN¥28.18
+33.3%
9.9%CN¥31.00CN¥23.70n/a4
Nov ’24CN¥20.24
CN¥28.18
+39.2%
9.9%CN¥31.00CN¥23.70CN¥12.634
Oct ’24CN¥21.31
CN¥28.18
+32.2%
9.9%CN¥31.00CN¥23.70CN¥14.124
Sep ’24CN¥22.09
CN¥28.18
+27.5%
9.9%CN¥31.00CN¥23.70CN¥12.334
Aug ’24CN¥23.36
CN¥28.90
+23.7%
12.8%CN¥32.00CN¥23.70CN¥12.593
Jul ’24CN¥23.25
CN¥28.90
+24.3%
12.8%CN¥32.00CN¥23.70CN¥13.803
Jun ’24CN¥24.26
CN¥30.67
+26.4%
4.1%CN¥32.00CN¥29.00CN¥16.953
May ’24CN¥26.58
CN¥30.67
+15.4%
4.1%CN¥32.00CN¥29.00CN¥17.433
Apr ’24CN¥28.42
CN¥30.50
+7.3%
4.9%CN¥32.00CN¥29.00CN¥18.212
Mar ’24CN¥30.43
CN¥30.50
+0.2%
4.9%CN¥32.00CN¥29.00CN¥16.502
Feb ’24CN¥29.03
CN¥30.50
+5.1%
4.9%CN¥32.00CN¥29.00CN¥15.242
Jan ’24CN¥27.36
CN¥30.50
+11.5%
4.9%CN¥32.00CN¥29.00CN¥22.652
Dec ’23CN¥28.21
CN¥30.50
+8.1%
4.9%CN¥32.00CN¥29.00CN¥21.132
Nov ’23CN¥28.05
CN¥28.05
0%
14.1%CN¥32.00CN¥24.10CN¥20.242

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.84

7D

-3.9%

1Y

14.4%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.44

7D

-2.0%

1Y

18.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.72

7D

-1.2%

1Y

18.8%